RAPTA-C

RAPTA-C (Ru (η6-p-cymene) Cl2 (pta) ) acts as an anti-cancer and anti-angiogenic agent. RAPTA-C exhibits anti-metastatic, anti-angiogenic, and anti-tumoral activities through protein and histone-deoxyribonucleic acid alterations. RAPTA-C exhibits cell growth inhibition by triggering G (2) /M phase arrest in cancer cells. RAPTA-C also enhances the levels of p53 and triggers the mitochondrial Apoptotic pathway, resulting in cytochrome C release and caspase-9 activation. RAPTA-C reduces the growth of tumors with the inhibition of angiogenesis in a ovarian carcinoma model[1][2][3].

Product Specifications

CAS Number

[372948-28-2]

Product Name Alternative

Ru (η6-p-cymene) Cl2 (pta)

UNSPSC

12352005

Target

Apoptosis; Caspase

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/rapta-c.html

Purity

99.30

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC12=C3[Ru+2]145(C6=C52)(P78C[N@@](C9)C[N@@](C[N@@]9C8)C7)([Cl-])([Cl-])C6(C(C)C)=C43

Molecular Formula

C16H23Cl2N3PRu

Molecular Weight

460.32

References & Citations

[1]Rausch M, et al. Recent considerations in the application of RAPTA‐C for cancer treatment and perspectives for its combination with immunotherapies[J]. Advanced Therapeutics, 2019, 2 (9) : 1900042.|[2]Weiss A, et al. In vivo anti-tumor activity of the organometallic ruthenium (II) -arene complex [Ru (η 6-p-cymene) Cl 2 (pta) ] (RAPTA-C) in human ovarian and colorectal carcinomas[J]. Chemical Science, 2014, 5 (12) : 4742-4748.|[3]Chatterjee S, et al. The ruthenium (II) -arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J Biol Inorg Chem. 2008 Sep;13 (7) :1149-55.